NBC 5 Chicago recently aired a segment on semaglutide misuse, spotlighting unregulated compounding of GLP-1 agonists. The report detailed patients injecting substances from questionable sources, often without medical oversight. For women, the hormonal interplay with these peptides adds another layer of concern. The story's warning is clear: the quest for weight loss can lead into dangerous territory when oversight disappears.
Semaglutide, a glucagon-like peptide-1 receptor agonist, was originally developed for type 2 diabetes. It slows gastric emptying and modulates appetite via central nervous system pathways. In women, endogenous GLP-1 secretion fluctuates across the menstrual cycle. Estrogen enhances the incretin effect during the follicular phase. This means the drug's impact may shift week to week.
Clinical trials established semaglutide's efficacy for weight management. The STEP trials enrolled thousands, with women comprising something like 70-80% of participants. At 2.4 mg weekly, mean weight loss reached roughly 15% of baseline body weight over 68 weeks (Wilding 2021). These results came from pharmaceutical-grade product, not compounded versions.
What the Research Supports
Randomized controlled trials provide the foundation for semaglutide's approved use. In STEP 1, 1,961 adults received semaglutide or placebo. The semaglutide group lost a mean of 14.9% body weight versus 2.4% for placebo (Wilding 2021). Women in the trial showed similar relative reductions. No pregnancy-specific data exist, as pregnant women were excluded.
Retatrutide, a triple agonist targeting GIP, GLP-1, and glucagon receptors, is under investigation. Phase 2 data showed dose-dependent weight loss up to 24.2% at 48 weeks (Jastreboff 2023). The female subset in that trial was around 55%. Menstrual cycle interactions remain unstudied for this compound. The FDA's evolving stance on peptide compounding could alter access before full approval.
Tirzepatide, a dual GIP/GLP-1 agonist, showed similar promise. In SURMOUNT-1, women lost up to 22.5% body weight at 72 weeks (Jastreboff 2022). These trials used tightly controlled manufacturing. Compounded versions lack such quality assurance. A comparison of retatrutide and tirzepatide highlights why purity matters.
Limitations of Current Evidence
Female-specific data are sparse. Most GLP-1 trials did not stratify by menstrual phase or menopausal status. Hormonal contraception use was rarely controlled. This leaves questions about efficacy variability. For example, luteal phase progesterone may blunt gastric emptying effects. The magnitude of this interaction is unknown.
Pregnancy safety is a black box. Animal studies show semaglutide causes fetal abnormalities at high doses. Human data are limited to inadvertent exposures. The drug's label carries a pregnancy warning. Women of reproductive age using compounded semaglutide may not receive adequate counseling. A case of severe GI side effects during Ramadan illustrates how physiological stressors amplify risks.
Compounding introduces additional unknowns. Unregulated pharmacies may use semaglutide sodium, a salt form not approved for human use. The NBC 5 report found patients injecting substances with unknown purity. Sterility cannot be guaranteed. One analysis of compounded GLP-1s found endotoxin levels exceeding safe limits in something like 10-15% of samples.
Open Questions
How does semaglutide affect ovulation? GLP-1 receptors exist in the ovary. Animal data suggest altered steroidogenesis. No human studies have tracked menstrual cyclicity during treatment. Anecdotal reports of cycle changes are common on social media. The mechanism could involve weight loss itself or direct receptor action. This remains unresolved.
What about long-term bone health? Estrogen protects bone density. Rapid weight loss can accelerate bone turnover. In postmenopausal women, this could increase fracture risk. The STEP trials did not include bone density endpoints. Retatrutide's glucagon agonism adds another variable, as glucagon influences calcium homeostasis. The retatrutide and tesamorelin stack raises similar questions about muscle and bone preservation.
Can compounding ever be safe? The FDA allows compounding during drug shortages. Semaglutide has been on the shortage list intermittently. This creates a gray market. Patients may not distinguish between legitimate compounding pharmacies and illicit operations. The NBC 5 investigation showed how easily one can obtain these products online. The question is whether regulatory frameworks can keep pace with demand.
How to Interpret What's Known
For clinicians, the priority is patient education. Women should understand that compounded GLP-1s are not generic equivalents. They lack the rigorous testing of branded products. Pregnancy must be avoided during treatment. Reliable contraception is essential. The drug's half-life of roughly one week means a washout period of at least two months before conception.
Monitoring should include menstrual diary and weight trends. Unexpected cycle changes warrant evaluation. Bone density screening may be prudent for long-term users, especially postmenopausal women. No guidelines exist for this, but clinical judgment suggests a baseline DEXA scan. The number needed to screen is unknown.
The NBC 5 warning underscores a broader problem. Demand for weight loss medications outstrips supply. This fuels unregulated markets. Women, who face disproportionate pressure regarding body weight, are particularly vulnerable. The solution is not simply more prescriptions. It requires addressing the root causes of misuse. What structural changes would reduce reliance on unregulated sources? That question remains open.
Common questions
Is compounded semaglutide the same as the brand-name drug?
No. Compounded semaglutide is made by pharmacies, not the original manufacturer. It may contain different salt forms or impurities. The FDA does not verify its safety or effectiveness. Studies show variability in potency and sterility. For women, this unpredictability is especially risky given hormonal interactions. Always verify the source and consult a healthcare provider.
Can semaglutide affect my menstrual cycle?
Possibly. GLP-1 receptors are present in the ovaries. Weight loss itself can alter cycles. Some women report changes in flow or timing. No formal studies have tracked this. If you notice irregularities, discuss them with your doctor. Tracking your cycle while on the medication is advisable.
What should I do if I become pregnant while taking semaglutide?
Stop the medication immediately and contact your healthcare provider. Semaglutide is not recommended during pregnancy. Animal data suggest potential fetal harm. Your doctor can guide you on monitoring and next steps. Do not resume the drug until after breastfeeding, if applicable.
How can I ensure my semaglutide is from a safe source?
Obtain it through a licensed pharmacy with a valid prescription. Check if the pharmacy is accredited by organizations like the Pharmacy Compounding Accreditation Board. Avoid online sellers that do not require a prescription. The NBC 5 report highlighted the dangers of unregulated sources. When in doubt, ask your doctor to verify the pharmacy's credentials.
All references to dosing in this article describe protocols used in published studies, not recommendations for individuals.